With the price of insulin tripling in a decade, pharmacists should not be surprised to see type 2 diabetes patients moving to other drugs that have not shown such dramatic increases, according to a new study. Researchers raise the issue of whether cost-benefit analysis justifies the continued use of insulin at such a high cost.